Navigation Links
Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/3/2008

FAIRFIELD, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced that Dr. Roger G. Berlin, Chief Executive Officer of Arno, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 2:00 PM EST in the Kennedy I room at the New York Palace Hotel in New York City. Dr. Berlin will provide a company overview and update on the status of Arno's current clinical development programs.

The presentation will be webcast live and can be accessed by visiting the Investor Relations second of Arno's website at http://www.arnothera.com. The webcast will be archived for 90 days.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel third-generation camptothecin analogue entering Phase II clinical development in patients with various forms of cancer. Arno has completed enrollment in a single agent, ascending dose, Phase I clinical study of AR-67 in patients with advanced solid tumors. AR-67 has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PDK1 inhibitor that blocks the PI3K/Akt pathway that is undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit http://www.arnothera.com.

Forward-Looking State
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
2. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
3. United Therapeutics Reports Third Quarter 2008 Financial Results
4. Arete Therapeutics Bolsters Management Team
5. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
8. Nektar Therapeutics to Webcast R&D Day on November 12th
9. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
10. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
11. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... food, functional food, and dietary supplement products with strong scientific ... ... North Brunswick, NJ and Blauvelt, NY (PRWEB) ... the crossroads of foods and pharmaceuticals, and RFI Ingredients, a ... signing of a Memorandum of Understanding (MOU) covering a range ...
(Date:12/16/2009)... by scientists at the University of East Anglia (UEA) ... domestic or agricultural waste to generate clean electricity. , ... of the National Academy of Sciences (PNAS), the ... by which some bacteria survive by ,breathing rocks,. , ... development of new microbe-based technologies such as fuel cells, ...
(Date:12/16/2009)... Technological University (NTU) signed the Memorandum of Understanding ... Research (CNRS) and the Thales Group of Companies ... three parties are meeting again in Singapore to ... NTU. , Located at the Research Techno ... latest in science and technology to develop innovations ...
(Date:12/16/2009)... Nursing Care at Hahnemann among the Best in ... -- Hahnemann University Hospital proudly announces it has ... Credentialing Center,s (ANCC) Magnet Recognition Program(R). Magnet(R) is ... hospital or medical center can achieve, and places ... the country that have achieved this prestigious distinction. ...
Breaking Biology Technology:WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 2WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 3'Rock-breathing' bacteria could generate electricity and clean up oil spills 2New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3
... announced today,that it is teaming up with BIOSAFE ... screenings to school age children in the greater,Richmond, ... children and,adolescents. Beginning May 1, 2008 and continuing ... available free of charge at any of the ...
... Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET), Financial Highlights, Item ... Q1 2008 (millions) Q1 2007 Comparison Total BioMarin Revenue ... 164.5% increase Naglazyme Net Product Revenue $27.7 ... $36.8 37.3% increase Aldurazyme ...
... 29 ,Anesiva, Inc. (Nasdaq: ANSV ) today ... with Green Vision Company, for,several Middle Eastern countries. ... approved in the U.S. to,provide topical local analgesia ... children three to 18 years of age., ...
Other Biology Technology:RediClinic, BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessments to Richmond, Va. School Children 2RediClinic, BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessments to Richmond, Va. School Children 3RediClinic, BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessments to Richmond, Va. School Children 4RediClinic, BIOSAFE Labs and Glycemion to Provide Free Diabetes Risk Assessments to Richmond, Va. School Children 5BioMarin Announces First Quarter 2008 Financial Results 2BioMarin Announces First Quarter 2008 Financial Results 3BioMarin Announces First Quarter 2008 Financial Results 4BioMarin Announces First Quarter 2008 Financial Results 5BioMarin Announces First Quarter 2008 Financial Results 6BioMarin Announces First Quarter 2008 Financial Results 7BioMarin Announces First Quarter 2008 Financial Results 8BioMarin Announces First Quarter 2008 Financial Results 9BioMarin Announces First Quarter 2008 Financial Results 10BioMarin Announces First Quarter 2008 Financial Results 11Anesiva Announces New Zingo Marketing and Distribution Agreement 2Anesiva Announces New Zingo Marketing and Distribution Agreement 3
(Date:12/17/2009)... reduced emissions from deforestation may generate multiple environmental ... that are both carbon and biodiversity-rich. , But ... Conservation Letters , also warns of challenges ... East Africa unless safeguards are followed. , This ... forest Degradation (REDD) might also displace and intensify ...
(Date:12/16/2009)... Scotland, Canada and the US have proposed a ... conservation. The team,s findings, published in Animal ... identified through feeding behaviour, can benefit highly mobile ... are enormous challenges associated with setting conservation priorities ... said lead author Erin Ashe, a PhD student ...
(Date:12/16/2009)... most out of every drop of water is a high priority ... hot and dry and vines have to be irrigated to make ... a significant portion of the water applied to the vines zips ... that about 10 percent of the water that is applied is ... with the soil and vine roots," said Eve Hinckley, who worked ...
Breaking Biology News(10 mins):New report underlines multiple benefits but also new challenges to biodiversity-rich sites 2New report underlines multiple benefits but also new challenges to biodiversity-rich sites 3Zoning the ocean may help endangered whales to recover 2Zoning the ocean may help endangered whales to recover 3Lost water of the Napa Valley vineyards 2Lost water of the Napa Valley vineyards 3Lost water of the Napa Valley vineyards 4LSUHSC research identifies enzyme that makes survival molecule for key vision cells 50167 1LSUHSC research identifies enzyme that makes survival molecule for key vision cells 50167 2In the warming West climate most significant factor in fanning wildfires flames 9017 1In the warming West climate most significant factor in fanning wildfires flames 9017 2Corals stay close to home 9014 1
... Interleukin-12 is a naturally occurring protein essential for ... either too much or too little interleukin-12 may play ... some cancers and auto-immune disorders like Crohn,s, psoriasis, and ... new therapies for those conditions. , In an effort ...
... of a commonly used meningitis vaccine may be as ... should allow scarce vaccine resources to be stretched further, ... initiated by the Norwegian Institute of Public Health, together ... Sans Frontires), and Mbarara University of Science and Technology ...
... Institute,s Workman Lab has discovered a novel histone demethylase ... Molecular Cell . , The Histone H3 protein ... wrapping up chromosomal DNA and preventing unwanted transcription of ... be altered by adding (methylating) or removing (demethylating) methyl ...
Other Biology News:Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants 2Novel bioreactor enhances interleukin-12 production in genetically modified tobacco plants 3Stowers Institute's Workman Lab discovers novel histone demethylase protein complex 2